| Characteristic | N = 231 |
|---|---|
| Age | 61 (12) |
| Sex | |
| female | 9 (39%) |
| male | 14 (61%) |
| Ethnicity | |
| Asian or Asian British | 5 (22%) |
| Black, Black British, Caribbean or African | 1 (4.3%) |
| Mixed or multiple ethnic groups | 1 (4.3%) |
| White | 16 (70%) |
| Any other ethnic group | 0 (0%) |
| Hypertension | 4 (17%) |
| Diabetes Type 2 | 2 (8.7%) |
| Dyslipidaemia | 1 (4.3%) |
| Smoking | 0 (0%) |
| Atrial Fibrillation | 5 (22%) |
| Stroke | 1 (4.3%) |
| Family History of SCD | 3 (14%) |
| Family History of Cardiomyopathy | 0 (0%) |
| Gene Positive | 8 (35%) |
| Gene Classification | |
| non pathogenic | 0 (0%) |
| VUS | 2 (25%) |
| pathogenic | 5 (63%) |
| likely pathogenic | 1 (13%) |
| likely non-pathogenic | 0 (0%) |
| not_applicable | 0 (0%) |
| missing | 0 (0%) |
| Variant | |
| 15 (65%) | |
| CSPR3 | 1 (4.3%) |
| MYBPC3 | 3 (13%) |
| MYH7 | 3 (13%) |
| TNNI3 | 1 (4.3%) |
| NSVT | 6 (30%) |
| CYP450 Metaboliser | |
| normal | 8 (35%) |
| rapid | 7 (30%) |
| intermediate | 5 (22%) |
| poor | 1 (4.3%) |
| ultrarapid | 2 (8.7%) |
| Bisoprolol | 15 (65%) |
| Verapamil | 7 (30%) |
| CIED | |
| no | 16 (70%) |
| PPM | 1 (4.3%) |
| ICD_transvenous | 3 (13%) |
| ICD_subcut | 2 (8.7%) |
| CRTP | 0 (0%) |
| CRTD | 0 (0%) |
| ILR | 1 (4.3%) |
| ICD indication | |
| prim_prevention | 5 (100%) |
| sec_prevention | 0 (0%) |
| Haemoglobin | 143 (17) |
| Haematocrit | 0.42 (0.05) |
| White Cell Count | 8.24 (2.54) |
| Creatinine | 90 (21) |
| eGFR | 69 (13) |
| Urea | 6.34 (1.77) |
| NT-proBNP | 1,077 (1,004) |
| hs Troponin T | 15 (7) |
| LVEDV Indexed (trabecular) | 71 (12) |
| LVEF (trabecular) | 80 (7) |
| LV Mass Indexed (trabecular) | 105 (32) |
| RVEDVi | 61 (10) |
| RVEF | 67 (9) |
| MAPSE | 13.06 (3.48) |
| LA Area Indexed | 17.4 (4.1) |
| RA Area Indexed | 10.06 (2.42) |
| Global Native T1 | 1,032 (39) |
| Global T2 | 48.53 (2.12) |
| ECV | 26.94 (3.35) |
| Global Stress MBF (mL/min/g) | 1.73 (0.41) |
| Global Rest MBF (mL/min/g) | 0.86 (0.21) |
| Global MPR | 2.10 (0.64) |
| Max LVOT gradient (mmHg) | 103 (39) |
| 1 Mean (SD); n (%) | |
The Effect of Mavacamten on Myocardial Perfusion in Obstructive Hypertrophic Cardiomyopathy
Preliminary
2025-10-31
Stress
| MBF (mL/min/g) | ||
|---|---|---|
| Timepoint | Mean | SE |
| Baseline | 1.44 | 0.05 |
| 2 months | 1.54 | 0.04 |
| 6 months | 1.63 | 0.06 |
Myocardial Perfusion Reserve
| MPR | ||
|---|---|---|
| Timepoint | Mean | SE |
| Baseline | 1.69 | 0.05 |
| 2 months | 1.98 | 0.05 |
| 6 months | 2.04 | 0.06 |
#1
#2
